U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults …
Oct 22, 2024 · ABRYSVO now offers the broadest RSV vaccine indication for adults, which previously included those 60 years and older. Additionally, it remains the only RSV immunization approved for pregnant individuals at 32 through 36 weeks of gestation to protect infants from birth up to 6 months of age.
RSV Vaccine Labeling Updated With Guillain-Barré Syndrome …
5 days ago · The labeling for Abrysvo and Arexvy has been updated to include a warning regarding Guillain-Barré syndrome.
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults …
Oct 22, 2024 · ABRYSVO now offers the broadest RSV vaccine indication for adults, which previously included those 60 years and older. Additionally, it remains the only RSV immunization approved for pregnant...
FDA Approves Abrysvo to Treat Adults 18 to 59 Years of Age at …
Oct 23, 2024 · Abrysvo is the first RSV vaccine approved for adults aged 18-49 at increased risk for RSV-LRTD due to chronic conditions. The vaccine targets the RSV fusion protein, a major neutralizing antibody target, providing protection against RSV-A and RSV-B.
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in ...
Aug 12, 2024 · ABRYSVO is a bivalent vaccine that was designed to provide protection against RSV-LRTD, regardless of the virus subgroup. In the prefusion state, the RSV fusion protein (F) is a major target of neutralizing antibodies, serving as the basis of Pfizer’s RSV vaccine.
FDA approves first RSV vaccine for at-risk adults younger than 50
Oct 28, 2024 · The U.S. Food and Drug Administration (FDA) has approved Abrysvo, a vaccine that protects against lung infections caused by the respiratory syncytial virus — commonly …
MONeT: RSV Vaccine Abrysvo Meets Endpoints in Adults 18 to 59 …
Apr 9, 2024 · Positive topline data were announced from the phase 3 MONeT trial evaluating a single dose of Abrysvo ® (respiratory syncytial virus vaccine) in adults 18 to 59 years of age at risk for developing severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD).
Pfizer touts positive topline data for RSV vaccine Abrysvo
Aug 12, 2024 · Pfizer has announced positive topline results from a pivotal late-stage study of its respiratory syncytial virus (RSV) vaccine, Abrysvo, in adults who are immunocompromised …
FDA Approves First Vaccine for Pregnant Individuals to Prevent …
FDA approves Abrysvo for immunization at 32 through 36 weeks gestational age of pregnancy to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus...
RSV Vaccine Abrysvo Approved for Use During Pregnancy to …
Aug 22, 2023 · US FDA approves Abrysvo™, Pfizer’s vaccine for the prevention of respiratory syncytial virus (RSV) in infants through active immunization of pregnant individuals 32-36 weeks of gestational age.